Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.63+5.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Recursion is improving with repeated earnings beats. It plans to keep cash burn under $390M in 2026. The company aims to last until early 2028 without new funding.
The company still loses money and has volatile management. Revenue is small and uncertain. Legal issues and leadership changes add risk.
The market expects about 42% revenue growth next year. Our fair value near $2.12 matches this growth view. We see risk in cash burn and losses.
Breaks if: annual cash burn exceeds $390 million in 2026
The company plans to manage expenses to extend its cash runway into early 2028 without additional financing.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is in a volatile sector with a focus on biotechnology. The current thesis state is weakened due to recent earnings misses and litigation, leading to increased uncertainty about future performance.
The market appears to be pricing in a high level of fragility given RXRX's expensive valuation compared to peers. There is an expectations gap, indicating that investors may not fully believe in the company's potential despite its optionality.
Management is focused on controlling cash burn and extending the cash runway, which is currently on track but mixed. Recent financial performance has been neutral, with a notable earnings miss impacting investor sentiment.
The thesis hinges on RXRX's ability to reverse its recent negative trends, particularly by raising guidance in the next quarter. Additionally, the performance of sector bellwethers and broader economic conditions will be crucial in shaping future outcomes.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
Yes, our read has weakened. Recent financial performance dropped from the robust half to the weak half of its sector. This change indicates a decline in the reasons to own the company. The market has not yet reacted to these weaker fundamentals, as the price is up 17% compared to the S&P.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: unexpected key executive departures occur
Breaks if: revenue growth falls below 30% in 2026
In the next 1 to 3 years, RXRX's prospects depend on management's execution and external market conditions. Not investment advice.